her2

Monogram Biosciences Inc. said it will begin offering a new test next week to diagnose patients with a very aggressive form of breast cancer.

The HERmark test, which will cost $3,350, will require that physicians send a biopsy sample to Monogram in South San Francisco, Calif. The service is to begin July 15.

Separately the Food and Drug Administration on Tuesday approved another new test for aggressive breast cancer called the SPOT-Light test by Invitrogen Corp. of Carlsbad, Calif. A spokeswoman said the test kits will be sold to hospital laboratories for about $1,400 for a packet of 20 kits.

Unlike Invitrogen’s test which is sold as a kit, Monogram’s HERmark test will be marketed as a service performed at its laboratories. Such tests are certified by a route different from the FDA, under the Clinical Laboratory Improvement Amendments (CLIA) by the Centers for Medicare and Medicaid Services, the company said. http://Louissheehan.BraveDiary.com

The new tests reflect the growing business of developing diagnostics that help doctors determine which patients are more likely to respond to often costly treatments and spare those who aren’t likely to be helped the cost and side effects that can accompany the drugs.

The new tests check patients for a form of cancer known as HER2-positive breast cancer because the tumor cells overproduce a protein called HER2. As many as a third of the breast-cancer cases in the U.S. — or 60,000 cases a year — are driven to aggressive spread by overactive HER2 genes, Monogram said.

Such cancers don’t respond well to conventional treatment, but are treatable with drugs such as Genentech Inc.’s Herceptin, or GlaxoSmithKline’s Tykerb. Abbott Laboratories and Dako Denmark A/S also market HER2 tests.

“The best methods to assess HER2 status remain controversial. We need to find better tests,” said Edith Perez, professor of medicine and chairperson of the breast cancer program for the Mayo Clinic in Jacksonville. She said further studies are needed to correlate new testing technologies with patient outcomes.

About 182,000 women will be diagnosed with breast cancer this year and 40,000 will die from it according to the American Cancer Society.

The new tests begin with a patient’s tumor samples, but use different technologies to assess HER2 activity. Invitrogen’s test counts copies of the HER2 gene, while Monogram’s test checks for levels of HER2 protein churned out by those genes. Monogram Biosciences Inc. said it will begin offering a new test next week to diagnose patients with a very aggressive form of breast cancer.

The HERmark test, which will cost $3,350, will require that physicians send a biopsy sample to Monogram in South San Francisco, Calif. The service is to begin July 15.

Separately the Food and Drug Administration on Tuesday approved another new test for aggressive breast cancer called the SPOT-Light test by Invitrogen Corp. of Carlsbad, Calif. http://louis-j-sheehan.biz
A spokeswoman said the test kits will be sold to hospital laboratories for about $1,400 for a packet of 20 kits.

Unlike Invitrogen’s test which is sold as a kit, Monogram’s HERmark test will be marketed as a service performed at its laboratories. Such tests are certified by a route different from the FDA, under the Clinical Laboratory Improvement Amendments (CLIA) by the Centers for Medicare and Medicaid Services, the company said.

The new tests reflect the growing business of developing diagnostics that help doctors determine which patients are more likely to respond to often costly treatments and spare those who aren’t likely to be helped the cost and side effects that can accompany the drugs.

The new tests check patients for a form of cancer known as HER2-positive breast cancer because the tumor cells overproduce a protein called HER2. As many as a third of the breast-cancer cases in the U.S. — or 60,000 cases a year — are driven to aggressive spread by overactive HER2 genes, Monogram said.

Such cancers don’t respond well to conventional treatment, but are treatable with drugs such as Genentech Inc.’s Herceptin, or GlaxoSmithKline’s Tykerb. Abbott Laboratories and Dako Denmark A/S also market HER2 tests.

“The best methods to assess HER2 status remain controversial. We need to find better tests,” said Edith Perez, professor of medicine and chairperson of the breast cancer program for the Mayo Clinic in Jacksonville. She said further studies are needed to correlate new testing technologies with patient outcomes.

About 182,000 women will be diagnosed with breast cancer this year and 40,000 will die from it according to the American Cancer Society. http://Louis2J2Sheehan2Esquire.US

The new tests begin with a patient’s tumor samples, but use different technologies to assess HER2 activity. Invitrogen’s test counts copies of the HER2 gene, while Monogram’s test checks for levels of HER2 protein churned out by those genes.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: